AAPL 190.415 0.3663% MSFT 422.65 -0.1016% GOOG 175.36 0.8512% GOOGL 174.14 0.9449% AMZN 185.71 -0.1505% NVDA 943.46 -0.3001% META 473.555 -1.6582% TSLA 174.87 0.5058% TSM 154.06 -0.977% LLY 776.1758 -1.3779% V 280.145 -0.2972% AVGO 1436.4972 0.0228% JPM 204.205 1.0366% UNH 522.225 0.9033% NVO 133.03 -1.2105% WMT 63.485 6.109% LVMUY 170.79 -0.2511% XOM 117.87 -0.5988% LVMHF 855.728 -0.1473% MA 461.6867 0.805%

Biosig Technologies Inc

Healthcare US BSGM

1.6USD
0.05(3.23%)

Last update at 2024-05-16T16:50:00Z

Day Range

1.501.64
LowHigh

52 Week Range

0.261.65
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -27.26200M -32.85600M -59.14000M -34.47068M -17.25132M
Minority interest 0.21M 0.94M 0.80M 0.52M 0.52M
Net income -27.27100M -31.36200M -52.17400M -33.92162M -17.25132M
Selling general administrative 21.38M 27.85M 40.95M 24.81M 12.88M
Selling and marketing expenses - - - - -
Gross profit 0.23M 0.24M - - 0.00000M
Reconciled depreciation 0.29M 0.20M 0.55M 0.05M 0.01M
Ebit -27.26500M -33.41100M -59.18400M -34.60388M -17.26221M
Ebitda -26.97200M -33.76600M -58.63300M -34.54998M -17.24981M
Depreciation and amortization 0.29M -0.35500M 0.55M 0.05M 0.01M
Non operating income net other - - -0.00100M 0.00045M -
Operating income -27.26500M -33.41100M -59.18400M -34.60388M -17.26221M
Other operating expenses 27.55M 33.85M 59.18M 34.60M 17.26M
Interest expense -0.00300M 0.00200M 0.04M 0.13M 0.01M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.00300M 0.00200M 0.04M 0.13M 0.01M
Net interest income 0.00300M 0.00200M 0.04M 0.13M 0.01M
Extraordinary items - - - - 3.20M
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00900M -1.49400M -6.96600M -0.54905M 0.02M
Total revenue 0.29M 0.44M 0.00000M 0.00000M 0.00000M
Total operating expenses 27.49M 33.65M 59.18M 34.60M 17.26M
Cost of revenue 0.06M 0.20M - - 0.00000M
Total other income expense net 0.00300M 0.56M 0.04M 0.13M 0.01M
Discontinued operations - - - - -
Net income from continuing ops -27.26200M -32.85600M -59.14000M -34.47068M -17.25132M
Net income applicable to common shares - -31.92600M -52.23208M -34.08016M -18.13605M
Preferred stock and other adjustments - - 0.01M 0.03M 0.88M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 4.11M 15.52M 30.39M 14.22M 5.00M
Intangible assets 0.31M 0.33M 0.35M 0.37M 0.27M
Earning assets - - - - -
Other current assets 0.00032M 0.35M 0.30M 0.14M 0.18M
Total liab 3.71M 2.95M 5.11M 2.34M 1.20M
Total stockholder equity 0.42M 12.35M 24.48M 11.36M 3.80M
Deferred long term liab - - - - -
Other current liab 2.94M 2.26M 4.79M 1.62M 1.20M
Common stock 0.06M 0.04M 0.03M 0.02M 0.02M
Capital stock 0.16M 0.14M 0.14M 0.24M 0.49M
Retained earnings -215.97400M -188.92200M -157.00500M -104.78677M -70.73194M
Other liab - 0.00500M - - -
Good will - - - - -
Other assets - 0.04M -0.00004M 0.13M 0.05M
Cash 0.36M 11.66M 28.27M 12.11M 4.45M
Cash and equivalents - - - - -
Total current liabilities 3.26M 2.58M 5.11M 2.03M 1.20M
Current deferred revenue 0.00500M 0.03M - - -
Net debt 0.41M -11.00300M -27.95400M -11.38516M -4.45016M
Short term debt 0.31M 0.28M 0.31M 0.41M -
Short long term debt - - - - -
Short long term debt total 0.77M 0.66M 0.31M 0.72M -
Other stockholder equity 216.23M 201.13M 181.34M 115.91M 74.13M
Property plant equipment - 1.26M 0.59M 0.89M 0.04M
Total current assets 1.13M 13.89M 29.34M 12.83M 4.63M
Long term investments - - - - -
Net tangible assets - 11.91M 24.02M 10.78M 3.05M
Short term investments 0.10M - - - -
Net receivables 0.00900M - - - -
Long term debt - - - - -
Inventory 0.34M 1.88M 0.77M 0.58M -
Accounts payable 0.00285M 0.00100M 0.03M 0.35M 0.95M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - 0.80M 0.51M -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - -0.44569M -0.09372M
Additional paid in capital - - - - -
Common stock total equity - - 0.03M 0.02M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity - - -157.00500M -104.78677M -70.73194M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.18M 0.04M 0.11M 0.13M 0.05M
Deferred long term asset charges - - - - -
Non current assets total 2.98M 1.62M 1.05M 1.39M 0.37M
Capital lease obligations 0.77M 0.66M 0.31M 0.72M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.16800M -0.54200M -0.08700M -0.28593M -0.30768M
Change to liabilities - -1.95000M 3.23M 0.54M 0.48M
Total cashflows from investing activities - -0.54200M -0.08700M -0.28593M -0.30768M
Net borrowings - - - - -
Total cash from financing activities 10.57M 10.33M 42.85M 23.43M 13.47M
Change to operating activities - -0.38600M -0.59500M -0.03209M -0.09585M
Net income -27.26200M -32.85600M -59.14000M -34.47068M -17.25132M
Change in cash -11.30200M -16.60900M 16.16M 7.66M 2.90M
Begin period cash flow 11.66M 28.27M 12.11M 4.45M 1.55M
End period cash flow 0.36M 11.66M 28.27M 12.11M 4.45M
Total cash from operating activities -21.70500M -26.39900M -26.60100M -15.48298M -10.25543M
Issuance of capital stock 10.35M 10.30M 27.44M 10.01M 10.63M
Depreciation 0.29M 0.20M 0.55M 0.05M 0.01M
Other cashflows from investing activities - - - -0.10884M -0.26965M
Dividends paid -0.00001M -0.00900M -0.18000M -0.39959M 0.74M
Change to inventory 0.28M -1.11400M -0.28700M -0.57769M -0.57769M
Change to account receivables -0.00900M 1.99M -3.23300M -0.53750M -
Sale purchase of stock - - 42.85M 23.43M 13.47M
Other cashflows from financing activities 0.22M 0.04M 15.58M 13.82M 5.07M
Change to netincome - 8.33M 22.72M 19.01M 6.60M
Capital expenditures 0.17M 0.54M 0.09M 0.29M 0.31M
Change receivables - - - - -
Cash flows other operating - - -0.13700M -0.03779M -0.09585M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 16.16M 7.66M 2.90M
Change in working capital 0.46M -3.45000M 2.35M -0.07228M 0.38M
Stock based compensation 4.41M 9.50M 25.16M 15.18M 6.60M
Other non cash items 0.39M 0.44M 4.47M 3.83M -5.34878M
Free cash flow -21.87300M -26.94100M -26.68800M -15.77167M -10.56311M

Fundamentals

  • Previous Close 1.55
  • Market Cap42.16M
  • Volume48888
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-28.99200M
  • Revenue TTM0.14M
  • Revenue Per Share TTM0.002
  • Gross Profit TTM 0.24M
  • Diluted EPS TTM-0.47

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BSGM
Biosig Technologies Inc
0.05 3.23% 1.60 - - 248.58 36.58 271.04 -1.3182
ABT
Abbott Laboratories
0.46 0.44% 105.05 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation
2.14 0.64% 334.13 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC
0.43 0.51% 85.15 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp
-0.185 0.25% 74.27 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

Profile

BioSig Technologies, Inc., together with its subsidiaries, a medical device company, commercializes advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias. The company offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for catheter ablation procedures for arrhythmias. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

Biosig Technologies Inc

55 Greens Farms Road, Westport, CT, United States, 06880

Key Executives

Name Title Year Born
Mr. Kenneth L. Londoner M.B.A., MBA Founder, CEO & Exec. Chairman 1968
Mr. Steven Chaussy CPA Chief Financial Officer 1954
Mr. John Sieckhaus Chief Operating Officer 1968
Dr. Budimir S. Drakulic Ph.D. Chief Scientist 1950
Mr. Andrew Gornell Ballou VP of Investor Relations NA
Ms. Brenda Castrodad VP of HR NA
Mr. Gray Fleming Jr. Chief Commercial Officer NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).